

## AACR Annual Meeting 2025

### Placeholder Abstract Submission Guidelines for Clinical Trials

All clinical trials abstracts must be submitted by January 16, 2025. A placeholder for a clinical trials abstract may be submitted to one of the Clinical Trials Placeholder categories (PL) only if the trial is ongoing, and final data are not available by the January 16 submission deadline but are expected to be collected between January 16 and February 18.

The placeholder abstract must be submitted by January 16, 2025.

Please note:

- Placeholder abstracts may be submitted for any phase trial (placeholder abstracts are not permitted for Trials in Progress.)
- A placeholder abstract should only be submitted if final data from an ongoing trial are not available by the January 16 deadline.
- Placeholder abstracts must be submitted to the appropriate PL category by January 16 and should include a tentative title, the full author list and disclosures, background information, and materials and methods. A description of any data that will be submitted with the final abstract should be added, including primary clinical endpoints, and dates and plans for the data analysis.
- A request and instructions will be sent to the submitting author to submit the updated final abstract by **February 18**.
- The Clinical Trials Committee will assess the placeholder abstract submission and then conduct a rapid review of the final abstract.

#### Placeholder Abstract Categories:

- PL02 Phase 0 Clinical Trials
- PL03 First-in-Human Phase I Clinical Trials
- PL04 Phase I Adult Clinical Trials
- PL05 Phase II Adult Clinical Trials
- PL06 Phase III Adult Clinical Trials
- PL07 Phase I, II, or III Clinical Trials in Pediatric Cancer
  - o Phase I Clinical Trials in Pediatric Cancer
  - o Phase II Clinical Trials in Pediatric Cancer
  - o Phase III Clinical Trials in Pediatric Cancer